Since our successful April 2024 launch demonstrating Troponin I & Myoglobin detection, we’ve been making rapid progress. By Q3 2025, we’ll secure Series A funding and manufacturing space while completing our four-biomarker detection system.
The final months of 2025 will see us deliver a complete prototype, integrating all four critical layers: advanced biosensors, optimized circuitry, robust firmware, and user-friendly apps. Parallel to these technical achievements, we’re building a strong IP portfolio, with our first biosensor patent filing in Q2 followed by four additional patents throughout the year.